{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05228041",
      "orgStudyIdInfo": {
        "id": "DRI_2021/0030"
      },
      "organization": {
        "fullName": "University Hospital, Lille",
        "class": "OTHER"
      },
      "briefTitle": "BIOlogics in Severe Nasal POlyposis SurvEy",
      "officialTitle": "Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps",
      "acronym": "BIOPOSE"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-02",
      "overallStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2022-02-10",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2027-07",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2027-07",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2021-12-17",
      "studyFirstSubmitQcDate": "2022-02-07",
      "studyFirstPostDateStruct": {
        "date": "2022-02-08",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-04-04",
      "lastUpdatePostDateStruct": {
        "date": "2022-04-12",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "University Hospital, Lille",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed.\n\nDuring the last 15 years, several studies have shown that CRSwNP is associated with a T helper 2 (T2) immune response leading to B cell release of IgE, mucosal recruitment of eosinophils from bone marrow via Interleukin (IL)-5, IL-4 and IL-13 mediated chemoattractant production.\n\nNew biologic agents capable of blocking T2 cytokines have been developed in the field of eosinophil-associated diseases, shifting the paradigm of treatment for patients with CRSwNP. In the near future, endotype profiling with accurate biomarkers will be mandatory to tailor the treatment of nasal polyposis with specific biologic therapies.\n\nHerein we propose a prospective study monitoring medical records of CRSwNP patients who undergo biologic treatments. The objectives are to assess treatment efficacy on quality of life, to report clinical and biological criteria for prescription and to measure tolerance and compliance."
    },
    "conditionsModule": {
      "conditions": [
        "Chronic Rhinosinusitis With Nasal Polyps"
      ],
      "keywords": [
        "Biologic",
        "nasal polyp",
        "chronic rhinosinusitis",
        "eosinophil",
        "endotype"
      ]
    },
    "designModule": {
      "studyType": "OBSERVATIONAL",
      "patientRegistry": false,
      "designInfo": {
        "observationalModel": "COHORT",
        "timePerspective": "PROSPECTIVE"
      },
      "enrollmentInfo": {
        "count": 100,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "interventions": [
        {
          "type": "DRUG",
          "name": "Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)",
          "description": "Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks)"
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "6-month rate of patients with a SNOT-22 (Sinonasal Outcome test -22) score change over the minimal clinically important difference of 8.9 by comparison of SNOT-22 scores measured at Month 0 and Month 6",
          "description": "from 0 to 110 , 110 = worst outcome",
          "timeFrame": "Day0, Month 6"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "SNOT 22 (Sinonasal Outcome Test-22) scores",
          "description": "from 0 to 110 , 110 = worst outcome",
          "timeFrame": "Day 0, Month 3, Month 6, Month 12 and Month 18"
        },
        {
          "measure": "Visual analogical scale (VAS) for nasal obstruction",
          "description": "from 0 to 10, 10 = worst outcome",
          "timeFrame": "Day 0, Month 3, Month 6, Month 12 and Month 18"
        },
        {
          "measure": "Visual analogical scale (VAS) for smell lost",
          "description": "from 0 to 10, 10 = worst outcome",
          "timeFrame": "Day 0, Month 3, Month 6, Month 12 and Month 18"
        },
        {
          "measure": "Visual analogical scale (VAS) for rhinorrhea",
          "description": "from 0 to 10, 10 = worst outcome",
          "timeFrame": "Day 0, Month 3, Month 6, Month 12 and Month 18"
        },
        {
          "measure": "Visual analogical scale (VAS) for craniofacial pain",
          "description": "from 0 to 10, 10 = worst outcome",
          "timeFrame": "Day 0, Month 3, Month 6, Month 12 and Month 18"
        },
        {
          "measure": "Number of systemic corticosteroid treatment courses between each visit",
          "timeFrame": "Day 0, Month 3, Month 6, Month 12 and Month 18"
        },
        {
          "measure": "Delay to first surgical procedure",
          "timeFrame": "Day 0, Month 3, Month 6, Month 12 and Month 18"
        },
        {
          "measure": "Blood eosinophil count",
          "description": "number of cells per mm3",
          "timeFrame": "Day 0, Month 3, Month 6, Month 12 and Month 18"
        },
        {
          "measure": "Blood total IgE concentrations",
          "description": "concentration expressed by KUI/L",
          "timeFrame": "Day 0, Month 3, Month 6, Month 12 and Month 18"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval\n\nExclusion Criteria:\n\n* Oral corticotherapy in the previous month;\n* Biologic treatment with anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab) or anti-IL-4/IL-13R (dupilumab) or any other biotherapy for inflammatory diseases in the previous 6 months apart from ongoing biotherapies for severe asthma;\n* Hypersensitivity to humanized antibodies ;\n* Documented SARS-Cov2 infection in the last 3 months with persistent olfactory disorders related to COVID;\n* Pregnant or breast-feeding women;\n* Patient without social coverage",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ],
      "studyPopulation": "Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval",
      "samplingMethod": "PROBABILITY_SAMPLE"
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Goeffrey Mortuaire, MD",
          "role": "CONTACT",
          "phone": "0320445962",
          "phoneExt": "+33",
          "email": "geoffrey.mortuaire@chru-lille.fr"
        }
      ],
      "overallOfficials": [
        {
          "name": "Geoffrey Mortuaire, MD",
          "affiliation": "University Hospital, Lille",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Hop Claude Huriez Chu Lille",
          "status": "RECRUITING",
          "city": "Lille",
          "zip": "59037",
          "country": "France",
          "contacts": [
            {
              "role": "CONTACT",
              "phone": "0320445962"
            }
          ],
          "geoPoint": {
            "lat": 50.63391,
            "lon": 3.05512
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "38749694",
          "type": "DERIVED",
          "citation": "Favier V, Daveau C, Carsuzaa F, Fieux M, Vandersteen C, Castillo L, Papon JF, de Gabory L, Saroul N, Verillaud B, Rumeau C, Jankowski R, Michel J, de Bonnecaze G, Lecanu JB, Coste A, Bequignon E, Malard O, Mortuaire G. Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey. BMJ Open. 2024 May 15;14(5):e083112. doi: 10.1136/bmjopen-2023-083112."
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D009298",
          "term": "Nasal Polyps"
        }
      ],
      "ancestors": [
        {
          "id": "D009668",
          "term": "Nose Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D010038",
          "term": "Otorhinolaryngologic Diseases"
        },
        {
          "id": "D011127",
          "term": "Polyps"
        },
        {
          "id": "D020763",
          "term": "Pathological Conditions, Anatomical"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C582203",
          "term": "dupilumab"
        },
        {
          "id": "C434107",
          "term": "mepolizumab"
        }
      ]
    }
  },
  "hasResults": false
}